Louise Photiou1, Carrie van der Weyden2, Christopher McCormack2, H Miles Prince2. 1. Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia. louise.photiou@gmail.com. 2. Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.
Abstract
PURPOSE OF REVIEW: Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma. Globally, the most common subtypes of CTCL are mycosis fungoides and Sézary syndrome. CTCL can confer significant morbidity and even mortality in advanced disease. Here we review the current and potential future treatments for advanced-stage CTCL. RECENT FINDINGS: Heterogeneity of treatment choice has been demonstrated both in US and non-US centers. Systemic treatment choice is currently guided by prognostic features, incorporating stage, immunophenotypic and molecular findings, and patient-specific factors such as age and comorbidities. Randomized controlled studies are uncommon, and the literature is composed predominantly of retrospective, cohort, and early-phase studies. International consensus guidelines are available; however, the lack of comparative trials means that there is no clear algorithmic approach to treatment. This review article reports on the systemic treatment options in current use for advanced CTCL, and on the possible future therapies, acknowledging that an algorithmic approach is not yet forthcoming to guide treatment prioritization.
PURPOSE OF REVIEW: Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma. Globally, the most common subtypes of CTCL are mycosis fungoides and Sézary syndrome. CTCL can confer significant morbidity and even mortality in advanced disease. Here we review the current and potential future treatments for advanced-stage CTCL. RECENT FINDINGS: Heterogeneity of treatment choice has been demonstrated both in US and non-US centers. Systemic treatment choice is currently guided by prognostic features, incorporating stage, immunophenotypic and molecular findings, and patient-specific factors such as age and comorbidities. Randomized controlled studies are uncommon, and the literature is composed predominantly of retrospective, cohort, and early-phase studies. International consensus guidelines are available; however, the lack of comparative trials means that there is no clear algorithmic approach to treatment. This review article reports on the systemic treatment options in current use for advanced CTCL, and on the possible future therapies, acknowledging that an algorithmic approach is not yet forthcoming to guide treatment prioritization.
Authors: P Tsirigotis; V Pappa; S Papageorgiou; V Kapsimali; V Giannopoulou; I Kaitsa; K Girkas; E Papageorgiou; N Stavrianeas; T Economopoulos; J Dervenoulas Journal: Br J Dermatol Date: 2007-04-25 Impact factor: 9.302
Authors: Youn H Kim; Mahkam Tavallaee; Uma Sundram; Katrin A Salva; Gary S Wood; Shufeng Li; Sima Rozati; Seema Nagpal; Michael Krathen; Sunil Reddy; Richard T Hoppe; Annie Nguyen-Lin; Wen-Kai Weng; Randall Armstrong; Melissa Pulitzer; Ranjana H Advani; Steven M Horwitz Journal: J Clin Oncol Date: 2015-07-20 Impact factor: 44.544
Authors: Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic Journal: J Clin Oncol Date: 2007-06-18 Impact factor: 44.544
Authors: E C Benton; S Crichton; R Talpur; N S Agar; P A Fields; E Wedgeworth; T J Mitchell; M Cox; S Ferreira; P Liu; A Robson; E Calonje; C M Stefanato; B Wilkins; J Scarisbrick; E M Wain; F Child; S Morris; M Duvic; S J Whittaker Journal: Eur J Cancer Date: 2013-06-01 Impact factor: 9.162
Authors: Linghua Wang; Xiao Ni; Kyle R Covington; Betty Y Yang; Jessica Shiu; Xiang Zhang; Liu Xi; Qingchang Meng; Timothy Langridge; Jennifer Drummond; Lawrence A Donehower; Harshavardhan Doddapaneni; Donna M Muzny; Richard A Gibbs; David A Wheeler; Madeleine Duvic Journal: Nat Genet Date: 2015-11-09 Impact factor: 38.330
Authors: Jevgenija Kondratjeva; Florie Julien; Céline Coutelier; Louis Humeau; Fabien Moog; Daniel Combarros; Isabelle Fourquaux; Charline Pressanti; Maxence Delverdier; Peter F Moore; Marie Christine Cadiergues Journal: BMC Vet Res Date: 2022-07-11 Impact factor: 2.792
Authors: N A Trum; J Zain; X U Martinez; V Parekh; M Afkhami; F Abdulla; K R Carson; S T Rosen; C L Bennett; C Querfeld Journal: Br J Dermatol Date: 2021-10-20 Impact factor: 9.302
Authors: Daniel Heudobler; Michael Rechenmacher; Florian Lüke; Martin Vogelhuber; Tobias Pukrop; Wolfgang Herr; Lina Ghibelli; Christopher Gerner; Albrecht Reichle Journal: Int J Mol Sci Date: 2018-11-09 Impact factor: 5.923
Authors: Belinda A Campbell; Gail Ryan; Christopher McCormack; Eleanor Tangas; Mathias Bressel; Robert Twigger; Odette Buelens; Carrie van der Weyden; H Miles Prince Journal: Cancers (Basel) Date: 2019-11-08 Impact factor: 6.639